Loading...
•
Dec 31, 2023
Tenaya Therapeutics Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
Key Takeaways
Tenaya Therapeutics reported its Q4 and full year 2023 financial results. The company highlighted the advancement of its genetic medicines portfolio, including progress with TN-201 and TN-401 gene therapy programs. A recent financing is expected to extend the cash runway into the second half of 2025.
First patient dosed in MyPEAK-1 Phase 1b clinical trial of TN-201 in October 2023.
On track to begin dosing in the RIDGE-1 Phase 1b clinical trial of TN-401 in the second half of 2024.
TN-401 received Fast Track Designation from the FDA in November.
Completed a follow-on offering in February 2024 with net proceeds of $46.5 million.
Forward Guidance
Tenaya expects that current funds, combined with net proceeds from the recent financing, will be sufficient to fund the company into the second half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...